PharmaCyte Biotech PMCB
NASDAQ PMCB
$0.39 -0.01 (-1.63%)
As of: Nov 12, 2026 · 10:14 AM EST

PharmaCyte Biotech (PMCB) Receivables - Other (2012 - 2013)

Updated

PharmaCyte Biotech (PMCB) reported Receivables - Other of $1.03 million for fiscal Q4 2013 (quarter ended Apr 30, 2013).

Analysis

PharmaCyte Biotech (PMCB) Receivables - Other (2012 - 2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 PharmaCyte Biotech 4.29 Mn -68.55 Mn -
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2013 1.03 Mn
Jan 31, 2013 1.03 Mn
Oct 31, 2012 1.03 Mn
Jul 31, 2012 1.03 Mn
Apr 30, 2012 1.03 Mn
API Access

PharmaCyte Biotech Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=PMCB&period=max&api_key=YOUR_API_KEY